KEY POINTS
1. A half loss of RUNX1 activity leads to defects in primitive erythropoiesis, megakaryopoiesis and proplatelet formation 2. An almost complete loss of RUNX1 activity leads to the amplification of granulomonocytic compartment with increased genomic instability FPD/AML is a suitable model to study the defects in megakaryopoiesis leading to thrombocytopenia. This disease can also be used to explore the initial events in leukemogenesis, as somatic alterations in the RUNX1 gene are involved in sporadic myeloid malignancies. Chromosomal translocations that involve the RUNX1 gene are commonly observed in acute myeloid leukemia (AML) 6 , whereas RUNX1 gene mutations are identified in 6-32% of AML [7] [8] [9] . Mutations in RUNX1 are also detected in 8-15% of chronic myelomonocytic leukemias 10, 11 and 9% of early stage myelodysplastic syndromes (MDS) 12 .
The fact that in MDS, RUNX1 mutations are detected at an early stage, before acute leukemia occurrence, argues for an early event in leukemic transformation 13 .
For personal use only. on April 5, 2017. by guest www.bloodjournal.org From Analysis of mouse models indicated that RUNX1 is a key regulator of definitive hematopoiesis, including HSC emergence 14 . In adult murine hematopoietic compartments, RUNX1 is dispensable for HSC maintenance, but negatively regulates myeloid progenitors while promoting lymphopoiesis and megakaryocytopoiesis 15, 16 . Regarding primitive hematopoiesis, an active yolk sac-derived erythropoiesis 14 and a normal number of primitive erythroid progenitors were observed in Runx-1 knock-out (KO) mice, but primitive erythrocytes had an abnormal morphology and a reduced expression of Ter119, Klf1 and
Gata1

17
. Conditional Runx1 KO led to the development of a myeloproliferative syndrome, but failed to reproduce the leukemic development observed in 35% of FPD/AML patients 15 .
Induced pluripotent stem cells (iPSC) 18 offer a new opportunity to model inherited human diseases in vitro and allow investigating initial pathogenic events that may occur during embryogenesis. Here, we generated iPSC from FPD/AML patients of two different pedigrees: one harbored the DN-like mutation R174Q 4 and the second a monoallelic RUNX1 deletion producing a true haploinsufficiency 2 . We first observed that RUNX1 played a crucial role in regulating the first wave of human primitive hematopoiesis, giving rise to erythroid and megakaryocytic cells. We noticed also that the phenotype induced by the R174Q mutant was similar to almost complete RUNX1 knock-down in human embryonic stem cells indicating that the R174Q RUNX1 mutation should affect the binding of the remaining wild type (WT) RUNX1 protein to CBFβ to induce an almost complete loss of function 3
. Most importantly, we noticed that increased genomic instability of granulomonocytic population depended on the dosage of functional RUNX1, which was associated with decreased expression of GADD45A 19 as well as other p53 targets. Overall, these results
show that the residual activity of wild-type RUNX1 protein would impact the risk for leukemia development in FPD/AML patients.
For personal use only. on April 5, 2017. by guest www.bloodjournal.org From
Material and methods
Cell culture
Human dermal fibroblasts (HDF) were derived from skin biopsies of patients after informed consent in accordance with the declaration of Helsinki. The study was approved by the Ethic Committee of INSERM RBM 01-14 for the project "Network on the inherited diseases of platelet function and platelet production".
They were cultured in F10 Glutamax medium (Invitrogen, Cergy Pontoise, France) with 20% fetal bovine serum (FBS) (Invitrogen, Cergy Pontoise, France). H9 human embryonic stem cell lines (hESC) (NIH code WA09) were obtained from WiCell Research Institute. iPSC and hESC were maintained at undifferentiated state on irradiated mouse embryonic fibroblasts (MEF) in hESC medium, as previously described 20 . The use of hESC was approved by
Agence of Biomedicine, N° R04-0020 and N° C04-0019. OP9 cells (Riken Institute, Japan) were maintained on gelatinized dishes.
IPSC generation.
HDF transduction with the STEMCCA lentivirus was performed at passage 4 or 5. HDF were transduced twice at 12 hrs intervals. Then, HDF (5x10 4 ) were plated on MEF and gelatin; 24 hrs later, the medium was replaced by hESC medium and changed every day. The ES likecolonies were picked up separately between day 30 and day 45 and cultivated as for hESC culture 21 . One iPSC control cell line (C1/ CHOPWT2.2) was already described 22 .
Hematopoietic differentiation on OP9 cells
To differentiate iPSC in hematopoietic cells, previously described protocols using co-culture on OP9 and cytokines (VEGF 20 ng/mL (Miltenyi Biotech) added at day 0 (D0), SCF 25ng/mL (Biovitrum AB, Stockholm, Sweden), IL-3 10ng/mL (Miltenyi Biotech), EPO 2U/mL (Amgen Thousand Oaks, CA), TPO 20ng/mL (Kirin Pharma Company, Tokyo, Japan) added at D7 of culture were used 20 .
Clonogenic progenitor assays
HSC/P were sorted on the expression of CD34, CD43 at D11 or D14 and plated in triplicate at a density of 1.5x10 3 cells/mL in human methylcellulose medium H4434 (StemCell Technologies, Vancouver, Canada) to quantify erythroid and CFU-G/M progenitors and at a density of 3x10 3 cells/mL in serum-free fibrin clots to quantify MK progenitors (MK-P). MK-P were stained with an anti-CD41a monoclonal antibody (BD Biosciences, Le Pont de Claix, France), as previously described 20 . Images were obtained with AxioVision 4.6 Software. The same software was used to measure the CFU-G/M colony size.
Gene expression analysis by conventional and quantitative real-time PCR
Genomic DNAs and RNAs were extracted using QIAmp DNA Mini Kit or RNeasy Micro Kit (Qiagen, Courtaboeuf, France). Reverse transcription of RNA was performed with SuperScript Vilo cDNA Synthesis Kit (Invitrogen, Cergy Pontoise, France). Q-RT-PCRs and Q-PCRs were performed on a 7500 Real-Time PCR using SYBR-Green PCR Master Mix (Applied Biosystems, Saint-Aubin, France). Expression levels of genes were normalized to housekeeping genes PPIA and L32. Primers used are listed in ST1. 
Statistical analyses
Results
RUNX1 alterations induce a defect in erythroid and megakaryocyte output.
To compare the consequences of two germline RUNX1 alterations, one leading to an increase in leukemia predisposition (R174Q mutation, pedigree A) and the other to thrombocytopenia alone (monoallelic deletion, pedigree D), four iPSC lines were derived from FPD/AML patient skin fibroblasts. The two pedigrees have been described previously 2, 4 . 
CD43
+ cells sorted at D11, we observed a decrease in the number of erythroid progenitors (Ery-P) generated from the RUNX1 R174Q mutated as well as RUNX1 haploinsufficient iPSC clones ( Figure 1A, B) . We also detected a 3-fold decrease in MK progenitor number for both pedigrees (Figure 1C, D Figure 1E, F) . The absolute numbers of erythroid (GPA + ) and of MK cells generated from 1x10 2 CD34 + CD43 + progenitors were decreased for both the RUNX1 R174Q mutation and RUNX1 deletion iPSC clones ( Figure 1G, H) . Strikingly, these results demonstrate that, in human, RUNX1 plays an important role in the first wave of hematopoiesis yielding primitive erythroid and MK cells.
Megakaryocytes derived from FPD/AML iPSC display a profound defect in proplatelet formation
When CD41 + CD42 + MKs were sorted after 14 days of co-culture and analyzed five days later (Figure 2A) , the percentage of proplatelet-forming MKs was decreased at least 10-fold in patient iPSC-compared to control iPSC-derived MKs ( Figure 2B, C) . Since RUNX1 is a positive or negative regulator of cytoskeleton components involved in proplatelet formation (MYL9, MYH9) 25 or in ploidization (MYH10)
26
, we examined the expression of these genes.
As observed in MKs derived from patient progenitors 25 , MYL9 expression level was decreased while MYH10 expression was increased in MKs obtained from patient iPSCs, whatever the RUNX1 alteration ( Figure 2D) , demonstrating that the defect in megakaryopoiesis is independent of the type of RUNX1 alteration.
RUNX1 R174Q mutation specifically affects the output of granulo-monocytes
When we assessed the G/M colony-forming potential of CD34 + CD43 + cells sorted at D14
(SF4A), we observed a significant 2-fold increase in the number of CFU-G/M in the two patients with R174Q mutation compared to the 3 controls ( Figure 3A ), but not in the patient with a monoallelic RUNX1 deletion ( Figure 3B) . The size of G/M colonies generated from
For personal use only. on April 5, 2017. by guest www.bloodjournal.org From R174Q iPSCs was also significantly increased ( Figure 3C ; median sizes 389420 µm 2 for AII_2 and 388953 µm 2 for AII_1 compared to 225078 µm 2 for C2). This size increase was not seen for iPSCs carrying the RUNX1 deletion ( Figure 3D (Fig 5H) .
Altogether, these results suggest that the differences between R174Q mutation and a monoallelic RUNX1 deletion can be explained by RUNX1 dosage. An almost complete functional inhibition or deletion, but not a haploinsufficiency, leads to the deregulation of the G/M compartment, which may contribute to leukemic development. Gene expression was then explored on hematopoietic CD34 
R174Q RUNX1 mutation but not haploinsufficiency leads to an increase in genomic instability
Gene expression analysis also demonstrated a slight decrease in four p53-dependent genes involved in DNA-damage response ( Figure 5J ). To explore the role of RUNX1 in genomic instability, we first sorted the CD43 + hematopoietic cells at D10 of culture from two FPD/AML iPSC lines with R174Q mutation and control iPSC lines. The accumulation of DNA double strain breaks (DSBs) was investigated using an antibody recognizing the phospho-histone H2AX (P-H2AX). As shown in Figure 6A , B, an increase in the number of + cell population, we did not detect any decrease in p21, NOXA and BAX expression, whatever the RUNX1 alteration ( Figure 6E ).
As the R174Q mutant cell line is characterized by an expansion of the G/M lineage, we focused on this population. As shown in Figure 6F and G, an increase in the number of Altogether, our results demonstrate that R174Q RUNX1 mutation could predispose to leukemic transformation at least partly through NR4A3 down-regulation and increased genomic instability in the G/M compartment, which is not observed with cells harboring a RUNX1 haploinsufficiency. Moreover, the additional decrease of RUNX1 activity in haploinsufficient iPS cells by the shRUNX1_1 led not only to an increase in CFU-G/M progenitor number but also to a decrease in p21 and GADD45A expression in the 
Discussion
The current approaches used to explore FPD/AML pathogenesis remain limited, as access to patient primary cells is difficult, due to the rarity of the disease. In addition, mouse models of Runx1 alterations do not completely reflect the phenotype observed in FPD/AML patients, e.g. adult mice with a conditional Runx1 KO develop a myeloproliferative /myelodysplastic syndrome rather than an acute leukemia 15 . Thus, to further explore the mechanisms of dysmegakaryopoiesis and sensitivity to leukemic transformation related to diverse RUNX1 alterations, we generated iPSC lines from two previously studied pedigrees:
one with a DN-like mutation R174Q and one with a RUNX1 monoallelic deletion. The two pedigrees are associated with thrombocytopenia, whereas only the first one is associated with AML.
The generation of hematopoietic progenitors during embryonic life occurs initially in large blood vessels by the formation of clusters derived from endothelial cells, a process that strikingly relies on the presence of RUNX1 28, 29 . The number of human hematopoietic progenitors generated from FPD/AML iPSC depends on the type of RUNX1 alteration 30 .
Here, we show that the knock-down of RUNX1 in embryonic stem cells limits the commitment to hematopoietic lineage at the clonal level. , which is highly associated with AML. However, this last mutation induces a deep defect in the generation of hematopoietic progenitors, which could be in some way also a preleukemic state as some aplastic anemia.
To our knowledge this is the first study that underlies the differences in granulomonocytic lineage between a haploinsufficiency alone and the DN-like R174Q RUNX1 mutant. These differences are clearly dependent on the protein dosage. is underscored by the example of PU.1, which needs to be decreased to less than 80% for inducing AML 42 whereas an haploinsufficiency has no effect 43, 44 .
Finally, we demonstrate that a RUNX1 loss of function leads to an increase in genomic instability linked to a decreased expression of p53-dependent genes and to an increase in the number of P53BP1 foci. Moreover, in the presence of the R174Q mutant, 10-fold more mutations occurred during the reprogramming process as compared to monoallelic RUNX1 deletion and control cell lines 45 . In line with these results, a novel role for RUNX1
during DNA damage response has been recently identified. Indeed, it cooperates with p53 after DNA damage and is recruited onto p53 target genes promoters 46 . In addition, a decreased expression of the direct RUNX1 target GADD45A, encoding for a sensor of DNA stress, was observed in bone marrow cells from MDS/AML patients harboring a RUNX1 mutation in C-terminal domain
19
. GADD45A was shown to be activated synergistically by RUNX1 and p53. Interestingly, Michaud et al reported previously a global genomic instability linked to RUNX1 impairment 47 and the incidence of RUNX1 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia is particularly high, revealing again a potential role of RUNX1 in genomic instability 48 .
In conclusion, whereas analysis of mouse models failed to identify any defect in primitive hematopoiesis, we show for the first time that RUNX1 germline alterations affect human embryonic hematopoiesis, particularly the generation of primitive erythroid and MK cells. As already described by others 30, 35 , defects in the generation of mature megakaryocytes do not depend on the type of RUNX1 variants. Conversely, a dominant negative R174Q mutant of RUNX1 increases the proliferative rate, and induces a genomic instability of G/M progenitors, thereby contributing to a preleukemic state development.
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